Keywords
Mostra di più Keywords
Sommario
  1. 1. Test clinico
  2. 2. Documentazione di routine
  3. 3. Registro / studio di coorte
  4. 4. Garanzia di qualità
  5. 5. Dati Standard
  6. 6. Risultato segnalato dal paziente
  7. 7. Specialità mediche
Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

25412 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Physician referral letter

- 27/09/21 - 1 modulo, 21 itemgroups, 341 elementi, 2 lingue
Itemgroups: Current episode, Transfer diagnosis, Other Diagnoses, Beta blocker, Calcium Channel Blockers, Angiotensin 2 Receptor Blocker, ACE inhibitors, Diuretics, Cardiac drugs, Antikoagulanzien, Antidiabetics , Antidepressive Agents, Neuroleptic Drugs, Hormonal contraceptives, Bronchodilator Agents, Antilipemic agent, Analgesics, Anti-Infective Agents, Antiparkinson Agents, Glucocorticoids, Other medication
derived from http://www.arztbriefmanager.de/ (Dr. Wolfram Arends, Tutzing, Germany)

26672_Common Data Elements Myeloid Leukemia (MDS AML CML) - Global Disease Course

- 20/09/21 - 13 moduli, 3 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Global Disease Course, Red Cell Transfusion, Platelet Cell Transfusion
Common Data Elements Myeloid Leukemia (MDS, AML, CML) for use in clinical routine and clinical trial documentation. https://www.ncbi.nlm.nih.gov/pubmed/27577388

Physical Examination/Follow up

3 itemgroups 14 elementi

Administrative/Demographic Details

1 ItemGroup 11 elementi

Medical History

3 itemgroups 9 elementi

Lab: Cytology/Cytogenetics/Cytochemistry

1 ItemGroup 29 elementi

Lab: Immunophenotyping

1 ItemGroup 17 elementi

Lab: Molecular Genetics

1 ItemGroup 27 elementi

CDASH Lab Result Assessment (Scenario 3, Part 2) - CDASH LAB Result Assessment (Scenario 3, Part 2)

- 20/09/21 - 1 modulo, 1 ItemGroup, 2 elementi, 2 lingue
ItemGroup: LAB Abnormal result
modified from http://www.cdisc.org

ICHOM Coronary Artery Disease - Peri-Inverventional Clinical Form

- 30/04/20 - 1 modulo, 8 itemgroups, 46 elementi, 1 linguaggio
Itemgroups: Administrative Data, Demographic factors, Baseline health status, Prior Treatments, TREATMENT VARIABLES, Acute complications of treatment, Major surgery complications, Major interventional cardiology complications
CORONARY ARTERY DISEASE DATA COLLECTION Version 2.0.3 Revised: April 5th, 2017 International Consortium for Health Outcomes Measurement (ICHOM), Source: http://www.ichom.org/ Notice: This work was conducted using resources from ICHOM, the International Consortium for Health Outcomes Measurement (www.ICHOM.org). The content is solely the responsibility of the authors and does not necessarily represent the official views of ICHOM. Conditions: Asymptomatic Coronary Artery Disease | Stable Angina | Acute Coronary Syndrome (Includes AMI) Treatment Approaches: Lifestyle Modification | Drug Therapy | Percutaneous Coronary Intervention (PCI) | Coronary Artery Bypass Grafting (CABG) This form contains peri-interventional clinical items. The items cover a timespan from prior to the intervention (e.g. PCI or CABG) until 30 days after it. They should be assessed at the entry event and at any new index event (e.g. new revascularization procedure or new diagnosis of ACS). Questionnaires used in this standard set: Rose Dyspnea Scale: The Rose Dyspnea Scale is free for all health care organizations, and a license is not needed. More information may be found at http://www.ahjonline.com/article/S0002-8703(09)00266-X/abstract Patient Health Questionnaire (PHQ-2): The PHQ-2 is free for all health care organizations, and a license is not needed. Copyright Pfizer, more Information on http://www.phqscreeners.com/ Seattle Angina Questionnaire (SAQ-7): Due to the need for a license for use of the SAQ-7 the actual questions of SAQ-7 will not be part of this version of the standard set. Publication: McNamara RL, Spatz ES, Kelley TA, et al. Standardized Outcome Measurement for Patients With Coronary Artery Disease: Consensus From the International Consortium for Health Outcomes Measurement (ICHOM). J Am Heart Assoc. 2015;4(5):e001767. Published 2015 May 19. doi:10.1161/JAHA.115.001767 For this version of the standard set, semantic annotation with UMLS CUIs has been added.

Telemedical Interventional Management in Heart Failure II (TIM-HF II) NCT01878630 - Baseline Visit

- 14/11/17 - 1 modulo, 10 itemgroups, 71 elementi, 2 lingue
Itemgroups: Physical Examination / Medical History taking, Signs and Symptoms of heart failure, Cardiovascular Diseases, Comorbidities, Current medication, Cardiovascular interventions, Implantation of a cardiac device, Hematology, ECG, Baseline visit
Short title: TIM-HF II Permission to publish granted by: Prof. Dr. Friedrich Köhler, FESC Charité - Universitätsmedizin Berlin Further study details on: https://www.clinicaltrials.gov/ct2/show/NCT01878630 Baseline Visit (BV-Form)

SF-36 (RAND)

- 17/09/21 - 1 modulo, 7 itemgroups, 36 elementi, 1 linguaggio
Itemgroups: General Info, Current health limitations, Physical Health related problems during past 4 weeks, Emotional problems during past 4 weeks, Past 4 weeks, Emotions in past 4 weeks, General statements
This document contains the 36-Item Short Form Survey Instrument Version 1 (SF-36) form, developed at RAND as part of the Medical Outcomes Study. RAND owns the copyright. All of the surveys and tools from RAND Health are public documents, available without charge. For more information - e.g. on terms and conditions for use or scoring instructions: https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form.html Changes made to the questionnaire should be made clearly identifiable.

CDASH ECG – Scenario 2 (local processing) - ECG – Scenario 2 (local processing)

- 20/06/18 - 1 modulo, 3 itemgroups, 16 elementi, 2 lingue
Itemgroups: General information, ECG Information (Local processing), ECG Results
modified from http://www.cdisc.org

NIHSS - NIH Stroke Scale

- 20/09/21 - 1 modulo, 1 ItemGroup, 16 elementi, 9 lingue
ItemGroup: NIHSS
https://en.wikipedia.org/wiki/National_Institutes_of_Health_Stroke_Scale

DACAPO-II Study - Verlegung vom Studienzentrum

- 31/01/22 - 6 moduli, 1 ItemGroup, 18 elementi, 1 linguaggio
ItemGroup: Zum Zeitpunkt der Verlegung
Das schwere akute Lungenversagen des Erwachsenen: Einfluss der Versorgungsqualität und individueller Patientenmerkmale auf die gesundheitsbezogene Lebensqualität bei Überlebenden (DACAPO) Surviving ARDS: the influence of quality of care and individual patient characteristics on health-related quality of life (DACAPO)

Demographische Daten

1 ItemGroup 11 elementi

CAM-ICU

1 ItemGroup 5 elementi

Interhospitaltransport

7 itemgroups 34 elementi

Externe Klinik

7 itemgroups 96 elementi

Studienzentrum

4 itemgroups 44 elementi

Stroke in French: Volet Accident Vasculaire Cérébral (AVC) - Risk factors (Facteurs de risque)

- 20/09/21 - 14 moduli, 6 itemgroups, 21 elementi, 3 lingue
Itemgroups: Hypertension, Diabetes, Lipid-lowering therapy, Tobacco use, Alcohol, Other
source: http://esante.gouv.fr/sites/default/files/asset/document/ci-sis_contenu_volet_avc_v2.1.0.pdf

Previous Therapy (Traitements en cours avant l'AVC)

2 itemgroups 4 elementi

Initial neurologic symptoms (Symptômes neurologiques initiaux)

1 ItemGroup 13 elementi

Header

4 itemgroups 17 elementi

Neurologic Examination (Examen Neurologique)

2 itemgroups 20 elementi

Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus Lab panels NCT00516321

- 20/09/21 - 1 modulo, 6 itemgroups, 71 elementi, 1 linguaggio
Itemgroups: Chemistry, Haematology, Liver Chemistry Assessments, Renal Laboratory Parameters, Urinalysis Dipstick, Other Laboratory Screenings
The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR). NCT00516321 https://clinicaltrials.gov/ct2/show/NCT00516321 Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a Plus Ribavirin

Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus Lab Panels NCT00529568

- 20/09/21 - 1 modulo, 6 itemgroups, 72 elementi, 1 linguaggio
Itemgroups: Chemistry, Haematology, Liver Chemistry Assessments, Renal Laboratory Parameters, Urinalysis Dipstick, Other Laboratory Screenings
The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR). NCT00529568 https://clinicaltrials.gov/ct2/show/NCT00529568 Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Treatment Official Title: Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2b Plus Ribavirin)

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial